Estimated number of prevalent cases of metastatic bone disease in the US adult population

Clinical Epidemiology

Volumn 4, Issue 1, 2012, Pages 87-93

  Li, Shuling ^a   Peng, Yi ^a   Weinhandl, Eric D ^a   Blaes, Anne H ^b   Cetin, Karynsa ^c   Chia, Victoria M ^c   Stryker, Scott ^c   Pinzone, Joseph J ^c   Acquavella, John F ^c   Arneson, Thomas J ^a  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c AMGEN INC   (United States)

Author keywords

Bone neoplasms; Epidemiology; Metastasis; Prevalence

Indexed keywords

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; COHORT ANALYSIS; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; PREVALENCE; PROSTATE CANCER; UNITED STATES;

EID: 84860878618     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S28339     Document Type: Article

References (22)

1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350(16):1655-1664.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165-176.
3. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9(Suppl 4):14-27.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243-6249.
5. Selvaggi G, Scagliotti G V. Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol. 2005;56(3):365-378.
6. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6(2):161-171.
7. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative beneft of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite frst-line bisphosphonate therapy. J Clin Oncol. 2006;24(30): 4895-4900.
8. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid signifcantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005;92(10):1869-1876.
9. Weinfurt K P, Li Y, Castel LD, Timbie J W, Glendenning GA, Schulman KA. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer [abstract 662P]. Ann Oncol. 2002;13(Suppl 5):180.
10. Weinfurt K P, Castel LD, Li Y, Timbie J W, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004;42(2):164-175.
11. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168(3):1005-1007.
12. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860-1867.
13. Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek J P, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal- related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011;129(2):495-503.
14. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek J P, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184(1):162-167.
15. Chia VM, Cetin K, Jacobsen JB, et al. The incidence and prognostic signifcance of bone metastases and skeletal-related events in lung cancer patients: a population-based cohort study in Denmark [Meeting Abstracts]. J Clin Oncol. 2010;28(15 Suppl e18074).
16. Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of US Medicare benefciaries, 1999-2006. Breast Cancer Res Treat. 2012;131(1):231-238.
17. Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare benefciaries, 1999-2006. Prostate Cancer Prostatic Dis. 2011;14(2):177-183.
18. Schulman KL, Kohles J. Economic burden of metastatic bone disease in the US. Cancer. 2007;109(11):2334-2342.
19. Sommers J. Updates to the Medical Expenditure Panel Survey Insurance Component List Sample Design, 2004. Methodology Report No 18. Available from: http://www.meps.ahrq.gov/mepsweb/data_fles/publications/mr18/mr18.pdf. Jan 2007. Accessed Jan 12, 2012.
20. US Census Bureau. Resident population by sex and age: 1980 to 2008. Available from: http://www.census.gov/compendia/statab/2010/tables/10s0007.pdf. Accessed January 12, 2012.
21. Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309-1312.
22. Jensen AØ, Nørgaard M, Yong M, Fryzek J P, Sørensen HT. Validity of the recorded International Classifcation of Diseases, 10th edition diagnoses codes of bone metastases and skeletal-related events in breast and prostate cancer patients in the Danish National Registry of Patients. Clin Epidemiol. 2009;1:101-108.